New 'Bone-Seeking' radiation drug enters human trials for advanced cancers
NCT ID NCT06982222
Summary
This is a first-in-human study to find a safe dose of a new radioactive drug, Sn-117m-DTPA, for patients whose prostate, breast, or non-small cell lung cancer has spread to their bones. The drug is designed to deliver radiation directly to bone tumors while trying to spare the healthy bone marrow. The main goals are to check for side effects and see if the treatment can slow or shrink the bone tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.